STERLING GI BRANDS COULD PROVIDE SUPPORT FOR SMITHKLINE'S CIMETIDINE
This article was originally published in The Tan Sheet
STERLING GI BRANDS COULD PROVIDE SUPPORT FOR SMITHKLINE'S CIMETIDINE as it moves from prescription to OTC status in more world markets. SmithKline Beecham is eyeing a world leadership position in the gastrointestinal OTC business with the combination of Sterling Winthrop's Phillips' Milk of Magnesia laxative, Dairy Ease and Andrews antacid brands with its own Tums, Gaviscon and Eno antacids, Citrucel laxative and the newly launched dyspepsia/heartburn medication, Tagamet 100, in the U.K. and New Zealand. Sterling's gastrointestinal business represents 17% of its total sales, while SmithKline's GI brands make up 28% of its OTC business.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC